GW Pharmaceuticals (GWP)

Business description

GW is a UK-based speciality pharma company developing cannabinoid medicines. Lead pipeline candidate Epidiolex is undergoing Phase III trials for childhood epilepsy. Sativex is marketed by partners in a number of EU countries for MS spasticity.

Stock data

Market cap.£1323.7m
Last close503.50p
High / Low (52 weeks)696.0p / 211.5p
Stock market listingLN, US
Forecast net cash (£m)152.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual7.5100.4(17.8)
Relative *7.694.5(9.8)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Acucela Addex Therapeutics
Adherium Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Capstone Therapeutics
Carmat Cell Therapy
Celldex Therapeutics Cellectis
Celyad Cerulean Pharma
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Consort Medical Corium International
Crossject Crossject SA
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Forward Pharma
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab Genticel
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
International Stem Cell Corporation Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Lifewatch AG Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech Pharma
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Oryzon Genomics Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
TearLab Corp Tekmira
TESARO Theraclion
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix Group
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals TruScreen Ltd
TxCell SA UCB
UDG Healthcare uniQure NV
Universal Biosensors VBI Vaccines
Vectura Verastem
Verisante Technology Vernalis
Verona Pharma PLC Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

This is Why GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Q1 Net Loss Should Not ...

Wed, 18 May 2016 10:34:55 GMT

GW Pharmaceuticals plc ($GWPH) Stock | Shares Double In Price On Positive Late ...

Tue, 15 Mar 2016 11:37:30 GMT

Are Analysts Bullish GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) After Last Week?

Fri, 27 May 2016 13:52:30 GMT

Perceptive Advisors LLC Decreased Stake in Gw Pharmaceuticals Plc (NASDAQ:GWPH ...

Thu, 26 May 2016 10:18:45 GMT

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) In Focus

Mon, 16 May 2016 11:02:13 GMT

Y/E Sep Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2014A 30.0 (17.0) (18.3) (6.4) N/A N/A
2015A 28.5 (54.6) (55.8) (17.6) N/A N/A
2016E 8.8 (79.9) (80.7) (25.4) N/A N/A
2017E 11.4 (78.2) (79.2) (23.9) N/A N/A

Last updated on 19/04/2016

Investment summary

GW Pharmaceuticals (GW) is developing an extensive cannabinoid portfolio with potential to treat a broad range of diseases. The lead pipeline asset is Epidiolex, now undergoing a multiple Phase III clinical study programme for refractory childhood epilepsies; initial top-line Phase III data from their trial in Dravet syndrome was statistically and clinically significant with a 39% reduction in the number of convulsive seizures (p=0.01). A second trial in Dravet is expected in H216. A Phase III trial in Lennox-Gastaut syndrome is due in Q216 and a second is due mid-year.

Last updated on 03/05/2016

Industry outlook

GW is the leading player in cannabinoid medicines. Cannabinoids are diverse chemical compounds that GW extracts from cannabis plant varieties (chemotypes) it has bred. Epidiolex has the potential to treat a broad range of treatment-refractory epilepsy conditions, while the portfolio extends to other orphan indication such as TSC epilepsy and NHIE.

Last updated on 03/05/2016

Key management

Geoffrey Guy, Chairman
Justin Gover, CEO
Adam David George, CFO

Company address

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom
+44 (0) 1980 557 000
View website